Company description

Alnylam Pharmaceuticals, Inc. (ticker: ALNY) is a biopharmaceutical company that focuses on developing innovative RNA interference (RNAi) therapeutics for the treatment of rare genetic, cardio-metabolic, and hepatic infectious diseases. Founded in 2002, the company has established itself as a leader in the field of RNAi technology, with multiple products in various stages of development. Alnylam's flagship product, Onpattro, was the first-ever RNAi therapeutic to receive FDA approval for the treatment of hereditary transthyretin-mediated amyloidosis, a rare and debilitating disease. The company also has a robust pipeline of potential treatments for other rare diseases, including acute hepatic porphyrias and primary hyperoxaluria type 1. In addition to its commitments to rare disease therapies, Alnylam has partnered with pharmaceutical giants like Sanofi, Novartis, and The Medicines Company to develop and commercialize treatments for more prevalent conditions like high cholesterol, chronic liver disease, and cardiovascular disease. The company has received numerous awards and recognition for its groundbreaking work in the field of RNAi, and continues to push the boundaries of science and medicine in order to bring life-saving treatments to patients worldwide. With a strong financial position and a dedicated team of visionary scientists and industry experts, Alnylam is poised for continued success and making a positive impact on the future of healthcare.